DOE OSTI · 1639131
Advancing How We Learn from Biodesign to Mitigate Risks with Next-Generation Genome Engineering
Abstract
In the last decade, the unprecedented simplicity and flexibility of the CRISPR-Cas system has made it the dominant transformative tool in gene and genome editing. However, this democratized technology is both a boon and a bane, for which we have yet to understand the full potential to investigate and rewrite genomes (also named “genome biodesign”). Rapid CRISPR advances in a range of applications in basic research, agriculture, and clinical applications pose new risks and raise several biosecurity concerns. In such a fast-moving field of research, we emphasize the importance of properly communicating the quality and accuracy of results and recommend new reporting requirements for results derived from next-generation genome engineering.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Abraham, Paul E., Labbé, Jessy L., McBride, Amber A.. 2020-04-25. Advancing How We Learn from Biodesign to Mitigate Risks with Next-Generation Genome Engineering. https://doi.org/10.34133/2020%2F9429650
Cite the original work for its findings. Save a collection to share your selection of sources.